Healios: retinal pigment epithelium (RPE) clinical trials from 2017

According to Healios’ CEO Hardy TS KAGIMOTO, Helios plans to start clinical trials with iPS-derived RPE in 2017 and hopes for approval in 2020. For international trials, cooperation with Lonza is envisioned.

Nikkei Biotech news release, June 30, 2015

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny